Evofem

About Aditx Therapeutics

Aditxt, Inc. is a publicly traded biotechnology company founded in 2018 with a mission to improve immune system health and address pressing health challenges. Its core strategy involves acquiring innovative companies and leveraging its proprietary 'aditXt' business acceleration platform to de-risk and scale these assets. The company's current portfolio includes programs in autoimmunity, early cancer detection, and neurological diagnostics, with a pipeline built entirely through acquisition and partnership.

Therapeutic Areas